UroGen Pharma Ltd. Ordinary Shares URGN

UroGen Pharma Ltd. es una empresa biofarmacéutica con sede en Israel. La compañía se dedica a desarrollar soluciones para el cáncer y enfermedades urológicas. UroGen ha desarrollado RTGelTM, un hidrogel termorregulable de liberación sostenida, una tecnología de plataforma patentada que tiene el potencial de mejorar perfiles terapéuticos de fármacos existentes. Sus principales candidatos a productos incluyen MitoGel y VesiGel, formulados utilizando su tecnología de hidrogel termorregulable, o RTGel, patentada. MitoGel (UGN-101) es una formulación de liberación sostenida del agente quimioterapéutico Mitomicina C para el tratamiento del carcinoma urotelial de bajo grado en el tracto superior. VesiGel (UGN-102) es una formulación de liberación sostenida de una alta dosis de Mitomicina C para el tratamiento del cáncer de vejiga no músculo-invasivo de bajo grado (LG-NMIBC).

• Zacks Investment Research 30 sept

  Here's Why You Should Add URGN Stock to Your Portfolio Now

  UroGen Pharma is transitioning from development-stage to commercial-growth biotech, driven by strong Zusduri uptake (73% sequential revenue growth to $50.4M in Q2 2026) and stable Jelmyto sales ($22M in Q2). The company's pipeline includes promising candidates like UGN-103 (94.5% response rate with NDA submitted) and UGN-104, with potential to expand beyond urothelial cancers through a strategic collaboration with IntraGel.

  

• Zacks Investment Research 8 sept

  Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

  Zacks highlights strong stock performance from its various rating systems and portfolios. Oportun Financial gained 31% after a Zacks Rank upgrade, Uranium Royalty advanced 67.6% following an Outperform recommendation, and Amgen returned 25.1% over 12 weeks. The article discusses economic conditions marked by geopolitical tensions, rising energy costs, and resilient but cooling labor markets, while showcasing the historical outperformance of Zacks' investment methodologies.

  

• GlobeNewswire Inc. 4 sept

  UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  UroGen Pharma Ltd. announced the grant of inducement restricted stock units (RSUs) to 19 new employees, with up to 117,100 ordinary shares issuable upon vesting over three years. The company also announced a strategic collaboration and investment agreement with IntraGel Therapeutics to access a biodegradable sustained-release gel platform and expand its uro-oncology and specialty cancer pipeline.

  

• The Motley Fool 12 jul

  UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run

  UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 10,000 shares worth $400,000 on July 9, 2026, under a pre-established Rule 10b5-1 trading plan adopted in August 2025. Despite the sale, Schoenberg retains 119,763 shares valued at $4.82 million. The transaction should not be viewed negatively as it was scheduled long in advance and the CMO maintains significant holdings. UroGen's Zusduri bladder cancer therapy is performing well with Q1 revenue jumping 152% to $51 million, and the company recently received FDA clearance for an investigational new drug application for UGN-501.

  

• The Motley Fool 14 jun

  Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

  UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 5,222 shares for approximately $143,000 on June 8, 2026, reducing his holdings by 3.60%. While his remaining stake of 139,763 shares keeps his interests aligned with investors, the sale follows a pattern of regular dispositions over the past year. The company faces headwinds from an upcoming generic competition agreement with Teva Pharmaceuticals for its flagship drug Jelmyto starting September 2030, though growth in other products like Zusduri may offset losses.